Peginterferon Alfa-2A

證據等級: L5

預測適應症: 10 個

Peginterferon alfa-2a: From Chronic Hepatitis C to Hepatitis B Virus Infection

One-Sentence Summary

Peginterferon alfa-2a (internationally marketed as Pegasys) is a pegylated interferon originally developed and used for chronic hepatitis C infection. The TxGNN model predicts it may also be effective for Hepatitis B Virus Infection, with 50 clinical trials and 20 publications currently identified supporting this direction — much of which reflects an already-established international indication rather than a purely novel hypothesis.

Quick Overview

Item	Content
Original Indication	Chronic hepatitis C (based on well-established international product information; Australia-specific approved indication text is a data gap — no ARTG entry exists)
Predicted New Indication	Hepatitis B Virus Infection
TxGNN Prediction Score	99.94%
Evidence Level	L1
Australia Market Status	Not marketed
Number of ARTG Entries	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Detailed mechanism of action data was not available in this evidence pack (data gap, High severity). Based on known information, Peginterferon alfa-2a is a pegylated form of interferon alfa-2a, an antiviral and immunomodulatory agent. Its efficacy in chronic hepatitis C has been well established internationally, and the same pharmacological class is already registered in many jurisdictions for chronic hepatitis B.

Chronic hepatitis B and chronic hepatitis C are both viral hepatitides in which interferon-based therapy suppresses viral replication and promotes host immune clearance. For hepatitis B specifically, pegylated interferon alfa is a textbook-level, guideline-recognised treatment: it inhibits HBV replication and drives immune-mediated clearance of viral antigen expression (including cccDNA-derived products). This is not a novel mechanistic hypothesis generated by the model — it reflects an already well-characterised therapeutic pathway, which is why the evidence base is unusually deep (50 trials, multiple landmark Phase 3 RCTs) compared with a typical de novo repurposing candidate.

In an Australian context, the practical significance of this “prediction” is less about mechanistic discovery and more about market access: the drug currently has zero ARTG entries and is not marketed locally, despite being an approved chronic hepatitis B therapy elsewhere.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrolment	Key Findings
NCT01641926	Phase 3	Terminated	402	Head-to-head comparison of PEG-Intron vs PEGASYS in HBeAg-positive and HBeAg-negative chronic hepatitis B
NCT00435825	Phase 4	Completed	551	4-arm study comparing PEGASYS duration (24 vs 48 weeks) and dose (90 vs 180 mcg) on HBeAg seroconversion and safety
NCT02598063	Phase 4	Completed	255	Peginterferon alfa-2a vs adefovir dipivoxil in lamivudine-resistant HBeAg-positive chronic hepatitis B
NCT01464281	N/A	Unknown	300	Multicentre study evaluating HBsAg clearance after switching from nucleotide analogues to peginterferon alfa-2a
NCT03181113	N/A	Completed	473	Long-term (5-year) cohort follow-up assessing durable benefit after standard peginterferon alfa therapy in HBeAg-positive CHB
NCT00877760	Phase 4	Completed	184	Temporary peginterferon alfa-2a add-on strategy to augment entecavir response in HBeAg-positive CHB
NCT01374308	Phase 3	Unknown	160	Therapeutic vaccine (NASVAC) vs peginterferon in chronic HBV infection
NCT00964665	Phase 1/2	Terminated	141	Pharmacokinetic/pharmacodynamic evaluation of an investigational combination in HBeAg-positive chronic hepatitis B
NCT01906580	Phase 4	Unknown	105	Combination or sequential therapy with peginterferon alfa-2a and entecavir in HBeAg-positive CHB
NCT01311947	N/A	Completed	103	Relationship between HBV mutants and therapeutic effect of peginterferon alfa-2a in HBeAg-positive CHB

Literature Evidence

PMID	Year	Type	Journal	Key Findings
15371578	2004	RCT	New England Journal of Medicine	Landmark trial: peginterferon alfa-2a alone, lamivudine alone, and combination in HBeAg-negative chronic hepatitis B
15987917	2005	RCT	New England Journal of Medicine	Landmark trial: peginterferon alfa-2a, lamivudine, and combination for HBeAg-positive chronic hepatitis B
30549279	2019	RCT	Hepatology	Entecavir and peginterferon alfa-2a in HBeAg-positive immune-tolerant chronic HBV infection (HBRN study)
30318613	2019	RCT	Hepatology	Entecavir/peginterferon alfa-2a combination in children with HBeAg-positive immune-tolerant chronic hepatitis B
30865588	2019	Systematic Review/Meta-analysis	Antiviral Therapy	Individual participant data meta-analysis defining peginterferon alfa-2a stopping rules in chronic hepatitis B
22045673	2011	Cohort/Post-hoc	Hepatology	Shorter durations/lower doses of peginterferon alfa-2a associated with inferior HBeAg seroconversion in genotypes B/C
29689122	2018	Phase 3 RCT	Hepatology	PEG-B-ACTIVE study: efficacy and safety of peginterferon alfa-2a in children with chronic hepatitis B
21423260	2011	Review	Nature Reviews Gastroenterology & Hepatology	Overview of hepatitis B therapy, including interferon-based approaches
29715359	2018	Review	JAMA	Review of chronic hepatitis B infection, including treatment landscape
26198336	2016	Review	Gut and Liver	Combination of pegylated interferon and nucleos(t)ide therapy toward a functional cure of HBV

Safety Considerations

Please refer to the TGA-approved Product Information (PI) for safety information. No structured safety data (warnings, contraindications, or drug interactions) is currently available for this evidence pack.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Chronic hepatitis B is supported by an unusually strong evidence base for a repurposing candidate — multiple completed Phase 3/4 RCTs, including two landmark NEJM trials, plus a formal stopping-rules meta-analysis. This largely reflects an internationally established indication rather than a new mechanistic hypothesis, but the drug currently has no ARTG registration and is not marketed in Australia, so guardrails are needed around regulatory and safety data before any local positioning.

To proceed, the following is needed:

TGA/ARTG-sourced Product Information covering warnings, contraindications, and drug interactions (currently a Blocking data gap)
Formally sourced mechanism of action documentation from DrugBank or equivalent (currently a High-severity data gap)
Confirmation of overseas regulatory status for chronic hepatitis B to inform an Australian registration pathway
Route-of-administration and formulation compatibility assessment for the Australian market (currently unassessed)

Note: Nine additional TxGNN-predicted indications for this drug were screened (hepatitis E, hepatitis A, veterinary hepatitis ontology terms, Omsk haemorrhagic fever, Kyasanur forest disease, and several cardiac conditions). All were assessed as L3–L5 evidence with a “Hold” recommendation, reflecting either niche/immunosuppressed-host use only (hepatitis E), lack of clinical rationale (self-limiting hepatitis A), or apparent disease-ontology/data-mapping errors (cardiac terms, animal hepatitis) — none are included in this report.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.